A drug boom with an unexpected side effect

Semaglutide's rise from a niche diabetes medication to one of the most prescribed injectable drugs in America has been well documented. Less discussed is what happened at poison control centers during that same stretch. Calls involving semaglutide — sold as Ozempic for type 2 diabetes and Wegovy for weight management — surged more than fivefold in the years following the FDA's 2021 approval of Wegovy for chronic weight management, climbing from roughly 1,500 calls per year to more than 8,000 by 2023, according to a study published in the Journal of Medical Toxicology.

What makes the finding notable isn't just the scale of the increase. It's the cause. Researchers found the surge wasn't driven by dangerous drug interactions, intentional misuse, or acute overdoses in any conventional sense. It came down almost entirely to two preventable, mechanical mistakes patients kept making with how they administered the drug.

The two mistakes behind thousands of calls

The first error: patients injecting semaglutide daily instead of weekly. Ozempic and Wegovy are both designed as once-weekly injections, taken on the same day each week — a dosing schedule that differs fundamentally from the daily-pill routines most patients are used to building habits around. A daily oral medication creates its own memory cue through repetition; a weekly injection requires patients to actively track timing across a full seven-day span, with no built-in daily reminder to anchor the routine.

The second error: patients starting treatment at the maximum dose rather than following the required gradual step-up schedule. Semaglutide's prescribing guidelines call for a slow dose escalation over several weeks specifically to let patients' bodies adjust and to minimize gastrointestinal side effects, which can be severe if the drug is introduced at full strength immediately. Skipping that titration period and starting at a high dose right away doesn't just risk stronger side effects — it's precisely the kind of therapeutic error that sends people to poison control lines seeking guidance on what to do next.

Where the research started: a curious undergraduate

The study originated with a straightforward question from Jordan Miller, then an undergraduate student at the University of Texas at San Antonio: was the surge in poison control calls actually connected to the FDA's expanded approval of semaglutide for weight management, or was the timing simply coincidental? Working with faculty, Miller analyzed poison control data to test that hypothesis directly, and the results left little ambiguity — the FDA's 2021 approval marked a clear inflection point, after which both the volume and the character of semaglutide-related poison control calls changed sharply.

Miller described being surprised by just how dominant semaglutide turned out to be in the data. "I wasn't expecting semaglutide to be so incredibly dominant," Miller said, reflecting on the analysis. "I figured that it would lead the pack, but it was staggering." A separate analysis specifically covering GLP-1 receptor agonist drugs as a category found that semaglutide accounted for 64% of all GLP-1-related poison control calls during the study period — a figure that reflects just how thoroughly the drug came to dominate its own broader medication class in terms of commercial reach and patient volume.

Why the delivery mechanism itself is part of the problem

Part of what's driving these errors traces back to how semaglutide reaches patients today compared to when it was primarily an endocrinologist-managed diabetes treatment. By late 2023, semaglutide products were among the most-prescribed branded injectable medications in the country, with millions of patients now accessing prescriptions through primary care offices, telehealth platforms, and, in some states, compounding pharmacies — settings that don't always carry the same depth of specialized patient education and monitoring that endocrinology practices historically provided for GLP-1 prescribing.

The physical delivery mechanism compounds that gap. Patients using pen-style injectors must track injection timing across a full week, navigate dose-adjustment schedules that change roughly every four weeks during the titration period, and distinguish between pens of different strengths that can look nearly identical on a refrigerator shelf. That's a considerably more complex self-management task than swallowing a daily pill, and it's exactly the kind of complexity that produces the two specific errors researchers identified as the leading causes behind the call surge.

Most cases were medically mild, but the pattern is instructive

It's worth being precise about severity here, since a fivefold surge in poison control calls can sound alarming out of context. A separate study published in the same journal, tracking every reported semaglutide-related exposure logged in a national poison center database from 2012 through 2023, found that unintentional therapeutic errors remained the most common reason people contacted poison centers — and that most of these cases were medically mild rather than life-threatening. That's an important distinction: this isn't primarily a story about a dangerous drug causing acute harm. It's a story about a drug whose administration routine is genuinely difficult for many patients to manage correctly without adequate guidance, generating a steady stream of avoidable, low-severity incidents at scale.

Kaitlyn Brown, a pharmacist and clinical managing director cited in coverage of the related poison center research, and other toxicology experts noted that dosing errors specifically tend to be more common among patients using compounded versions of semaglutide — products manufactured outside the FDA-regulated branded pipeline, often with less standardized dosing guidance and packaging than the name-brand Ozempic or Wegovy pens.

What researchers are recommending going forward

The study's authors are calling for these findings to be built directly into prescriber education and patient counseling standards, with particular emphasis on primary care offices and telehealth platforms — the settings now responsible for initiating the vast majority of new semaglutide prescriptions, and the settings furthest removed from the specialized endocrinology oversight that once governed GLP-1 drug prescribing almost exclusively.

That's a comparatively simple, low-cost intervention relative to the scale of the problem it addresses. Sunny Han, a co-author involved in the broader data science analysis of the trend, framed the value of the work in practical terms: quantifying exactly how a specific drug's expanded approval translated into a measurable public health pattern is what allows researchers and prescribers to target interventions precisely, rather than treating the surge as a vague, unexplained side effect of the drug's popularity. Researchers say tracking whether call rates stabilize, decline, or continue climbing as Medicare coverage expands the patient base further will be critical for determining whether improved patient education and counseling standards are actually closing the gap responsible for thousands of preventable calls each year.

*This article was researched using publicly available reporting from ScienceDaily, the University of Texas at San Antonio, Medical Daily, StudyFinds, Mirage News, and the peer-reviewed studies published in the Journal of Medical Toxicology and Significance. It is intended for informational purposes and is not medical advice. If you are experiencing a medication-related emergency, contact Poison Control or seek immediate medical attention.*